Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials
University of Colorado Anschutz Medical Campus · Memorial Sloan Kettering Cancer Center · +42 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,728
total citations
- FWCI
- 134.78
- Percentile
- 100%
- References
- 33
Citations per year
Authors
38- RCRobert C. Doebele
University of Colorado Anschutz Medical Campus
- ADAlexander Drilon
Memorial Sloan Kettering Cancer Center, Cornell University
- LPLuis Paz‐Ares
Hospital Universitario 12 De Octubre
- SSSalvatore Siena
University of Milan, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
- ATAlice T. Shaw
Massachusetts General Hospital
Topics & keywords
Topics
Keywords
- Trk receptor
- Medicine
- Internal medicine
- Oncology
- Population
- Clinical trial
- Cancer
- Phases of clinical research
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.